Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine

Dennis MacKin, Yupeng Li, Michael B. Taylor, Matthew Kerr, Charles Holmes, Narayan Sahoo, Falk Poenisch, Heng Li, Jim Lii, Richard Amos, Richard Wu, Kazumichi Suzuki, Michael T. Gillin, X. Ronald Zhu, Xiaodong Zhang

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to validate the use of HPlusQA, spot-scanning proton therapy (SSPT) dose calculation software developed at The University of Texas MD Anderson Cancer Center, as second-check dose calculation software for patient-specific quality assurance (PSQA). The authors also showed how HPlusQA can be used within the current PSQA framework. Methods: The authors compared the dose calculations of HPlusQA and the Eclipse treatment planning system with 106 planar dose measurements made as part of PSQA. To determine the relative performance and the degree of correlation between HPlusQA and Eclipse, the authors compared calculated with measured point doses. Then, to determine how well HPlusQA can predict when the comparisons between Eclipse calculations and the measured dose will exceed tolerance levels, the authors compared gamma index scores for HPlusQA versus Eclipse with those of measured doses versus Eclipse. The authors introduce the αβγ transformation as a way to more easily compare gamma scores. Results: The authors compared measured and calculated dose planes using the relative depth, z/R × 100%, where z is the depth of the measurement and R is the proton beam range. For relative depths than less than 80%, both Eclipse and HPlusQA calculations were within 2 cGy of dose measurements on average. When the relative depth was greater than 80%, the agreement between the calculations and measurements fell to 4 cGy. For relative depths less than 10%, the Eclipse and HPlusQA dose discrepancies showed a negative correlation, -0.21. Otherwise, the correlation between the dose discrepancies was positive and as large as 0.6. For the dose planes in this study, HPlusQA correctly predicted when Eclipse had and had not calculated the dose to within tolerance 92% and 79% of the time, respectively. In 4 of 106 cases, HPlusQA failed to predict when the comparison between measurement and Eclipse's calculation had exceeded the tolerance levels of 3% for dose and 3 mm for distance-to-agreement. Conclusions: The authors found HPlusQA to be reasonably effective (79% ± 10%) in determining when the comparison between measured dose planes and the dose planes calculated by the Eclipse treatment planning system had exceeded the acceptable tolerance levels. When used as described in this study, HPlusQA can reduce the need for patient specific quality assurance measurements by 64%. The authors believe that the use of HPlusQA as a dose calculation second check can increase the efficiency and effectiveness of the QA process.

Original languageEnglish (US)
Article number121708
JournalMedical physics
Volume40
Issue number12
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Proton Therapy
Software
Protons
Therapeutics
Neoplasms

Keywords

  • Gamma index
  • IMPT
  • Patient quality assurance
  • Proton therapy
  • Spot scanning
  • γ index

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine. / MacKin, Dennis; Li, Yupeng; Taylor, Michael B.; Kerr, Matthew; Holmes, Charles; Sahoo, Narayan; Poenisch, Falk; Li, Heng; Lii, Jim; Amos, Richard; Wu, Richard; Suzuki, Kazumichi; Gillin, Michael T.; Zhu, X. Ronald; Zhang, Xiaodong.

In: Medical physics, Vol. 40, No. 12, 121708, 01.01.2013.

Research output: Contribution to journalArticle

MacKin, D, Li, Y, Taylor, MB, Kerr, M, Holmes, C, Sahoo, N, Poenisch, F, Li, H, Lii, J, Amos, R, Wu, R, Suzuki, K, Gillin, MT, Zhu, XR & Zhang, X 2013, 'Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine', Medical physics, vol. 40, no. 12, 121708. https://doi.org/10.1118/1.4828775
MacKin, Dennis ; Li, Yupeng ; Taylor, Michael B. ; Kerr, Matthew ; Holmes, Charles ; Sahoo, Narayan ; Poenisch, Falk ; Li, Heng ; Lii, Jim ; Amos, Richard ; Wu, Richard ; Suzuki, Kazumichi ; Gillin, Michael T. ; Zhu, X. Ronald ; Zhang, Xiaodong. / Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine. In: Medical physics. 2013 ; Vol. 40, No. 12.
@article{3094bd52822f46758e5af8b2b87f2b2a,
title = "Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine",
abstract = "Purpose: The purpose of this study was to validate the use of HPlusQA, spot-scanning proton therapy (SSPT) dose calculation software developed at The University of Texas MD Anderson Cancer Center, as second-check dose calculation software for patient-specific quality assurance (PSQA). The authors also showed how HPlusQA can be used within the current PSQA framework. Methods: The authors compared the dose calculations of HPlusQA and the Eclipse treatment planning system with 106 planar dose measurements made as part of PSQA. To determine the relative performance and the degree of correlation between HPlusQA and Eclipse, the authors compared calculated with measured point doses. Then, to determine how well HPlusQA can predict when the comparisons between Eclipse calculations and the measured dose will exceed tolerance levels, the authors compared gamma index scores for HPlusQA versus Eclipse with those of measured doses versus Eclipse. The authors introduce the αβγ transformation as a way to more easily compare gamma scores. Results: The authors compared measured and calculated dose planes using the relative depth, z/R × 100{\%}, where z is the depth of the measurement and R is the proton beam range. For relative depths than less than 80{\%}, both Eclipse and HPlusQA calculations were within 2 cGy of dose measurements on average. When the relative depth was greater than 80{\%}, the agreement between the calculations and measurements fell to 4 cGy. For relative depths less than 10{\%}, the Eclipse and HPlusQA dose discrepancies showed a negative correlation, -0.21. Otherwise, the correlation between the dose discrepancies was positive and as large as 0.6. For the dose planes in this study, HPlusQA correctly predicted when Eclipse had and had not calculated the dose to within tolerance 92{\%} and 79{\%} of the time, respectively. In 4 of 106 cases, HPlusQA failed to predict when the comparison between measurement and Eclipse's calculation had exceeded the tolerance levels of 3{\%} for dose and 3 mm for distance-to-agreement. Conclusions: The authors found HPlusQA to be reasonably effective (79{\%} ± 10{\%}) in determining when the comparison between measured dose planes and the dose planes calculated by the Eclipse treatment planning system had exceeded the acceptable tolerance levels. When used as described in this study, HPlusQA can reduce the need for patient specific quality assurance measurements by 64{\%}. The authors believe that the use of HPlusQA as a dose calculation second check can increase the efficiency and effectiveness of the QA process.",
keywords = "Gamma index, IMPT, Patient quality assurance, Proton therapy, Spot scanning, γ index",
author = "Dennis MacKin and Yupeng Li and Taylor, {Michael B.} and Matthew Kerr and Charles Holmes and Narayan Sahoo and Falk Poenisch and Heng Li and Jim Lii and Richard Amos and Richard Wu and Kazumichi Suzuki and Gillin, {Michael T.} and Zhu, {X. Ronald} and Xiaodong Zhang",
year = "2013",
month = "1",
day = "1",
doi = "10.1118/1.4828775",
language = "English (US)",
volume = "40",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "12",

}

TY - JOUR

T1 - Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine

AU - MacKin, Dennis

AU - Li, Yupeng

AU - Taylor, Michael B.

AU - Kerr, Matthew

AU - Holmes, Charles

AU - Sahoo, Narayan

AU - Poenisch, Falk

AU - Li, Heng

AU - Lii, Jim

AU - Amos, Richard

AU - Wu, Richard

AU - Suzuki, Kazumichi

AU - Gillin, Michael T.

AU - Zhu, X. Ronald

AU - Zhang, Xiaodong

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: The purpose of this study was to validate the use of HPlusQA, spot-scanning proton therapy (SSPT) dose calculation software developed at The University of Texas MD Anderson Cancer Center, as second-check dose calculation software for patient-specific quality assurance (PSQA). The authors also showed how HPlusQA can be used within the current PSQA framework. Methods: The authors compared the dose calculations of HPlusQA and the Eclipse treatment planning system with 106 planar dose measurements made as part of PSQA. To determine the relative performance and the degree of correlation between HPlusQA and Eclipse, the authors compared calculated with measured point doses. Then, to determine how well HPlusQA can predict when the comparisons between Eclipse calculations and the measured dose will exceed tolerance levels, the authors compared gamma index scores for HPlusQA versus Eclipse with those of measured doses versus Eclipse. The authors introduce the αβγ transformation as a way to more easily compare gamma scores. Results: The authors compared measured and calculated dose planes using the relative depth, z/R × 100%, where z is the depth of the measurement and R is the proton beam range. For relative depths than less than 80%, both Eclipse and HPlusQA calculations were within 2 cGy of dose measurements on average. When the relative depth was greater than 80%, the agreement between the calculations and measurements fell to 4 cGy. For relative depths less than 10%, the Eclipse and HPlusQA dose discrepancies showed a negative correlation, -0.21. Otherwise, the correlation between the dose discrepancies was positive and as large as 0.6. For the dose planes in this study, HPlusQA correctly predicted when Eclipse had and had not calculated the dose to within tolerance 92% and 79% of the time, respectively. In 4 of 106 cases, HPlusQA failed to predict when the comparison between measurement and Eclipse's calculation had exceeded the tolerance levels of 3% for dose and 3 mm for distance-to-agreement. Conclusions: The authors found HPlusQA to be reasonably effective (79% ± 10%) in determining when the comparison between measured dose planes and the dose planes calculated by the Eclipse treatment planning system had exceeded the acceptable tolerance levels. When used as described in this study, HPlusQA can reduce the need for patient specific quality assurance measurements by 64%. The authors believe that the use of HPlusQA as a dose calculation second check can increase the efficiency and effectiveness of the QA process.

AB - Purpose: The purpose of this study was to validate the use of HPlusQA, spot-scanning proton therapy (SSPT) dose calculation software developed at The University of Texas MD Anderson Cancer Center, as second-check dose calculation software for patient-specific quality assurance (PSQA). The authors also showed how HPlusQA can be used within the current PSQA framework. Methods: The authors compared the dose calculations of HPlusQA and the Eclipse treatment planning system with 106 planar dose measurements made as part of PSQA. To determine the relative performance and the degree of correlation between HPlusQA and Eclipse, the authors compared calculated with measured point doses. Then, to determine how well HPlusQA can predict when the comparisons between Eclipse calculations and the measured dose will exceed tolerance levels, the authors compared gamma index scores for HPlusQA versus Eclipse with those of measured doses versus Eclipse. The authors introduce the αβγ transformation as a way to more easily compare gamma scores. Results: The authors compared measured and calculated dose planes using the relative depth, z/R × 100%, where z is the depth of the measurement and R is the proton beam range. For relative depths than less than 80%, both Eclipse and HPlusQA calculations were within 2 cGy of dose measurements on average. When the relative depth was greater than 80%, the agreement between the calculations and measurements fell to 4 cGy. For relative depths less than 10%, the Eclipse and HPlusQA dose discrepancies showed a negative correlation, -0.21. Otherwise, the correlation between the dose discrepancies was positive and as large as 0.6. For the dose planes in this study, HPlusQA correctly predicted when Eclipse had and had not calculated the dose to within tolerance 92% and 79% of the time, respectively. In 4 of 106 cases, HPlusQA failed to predict when the comparison between measurement and Eclipse's calculation had exceeded the tolerance levels of 3% for dose and 3 mm for distance-to-agreement. Conclusions: The authors found HPlusQA to be reasonably effective (79% ± 10%) in determining when the comparison between measured dose planes and the dose planes calculated by the Eclipse treatment planning system had exceeded the acceptable tolerance levels. When used as described in this study, HPlusQA can reduce the need for patient specific quality assurance measurements by 64%. The authors believe that the use of HPlusQA as a dose calculation second check can increase the efficiency and effectiveness of the QA process.

KW - Gamma index

KW - IMPT

KW - Patient quality assurance

KW - Proton therapy

KW - Spot scanning

KW - γ index

UR - http://www.scopus.com/inward/record.url?scp=84890113220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890113220&partnerID=8YFLogxK

U2 - 10.1118/1.4828775

DO - 10.1118/1.4828775

M3 - Article

C2 - 24320494

AN - SCOPUS:84890113220

VL - 40

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 12

M1 - 121708

ER -